Early efforts in cystic fibrosis (CF) gene therapy faced major challenges in delivery efficiency and sustained therapeutic gene expression. Recent advancements in engineered site-specific endonucleases such as clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 make permanent CF transmembrane conductance regulator (CFTR) gene correction possible. However, because of safety concerns of the CRISPR/Cas9 system and challenges in in vivo delivery to inflamed CF airway, CRISPR-based gene correction strategies need to be tested in proper animal models. In this study, we aimed at creating vectors for testing CFTR gene correction in pig models. We constructed helper-dependent adenoviral (HD-Ad) vectors to deliver CRISPR/Cas9 and a donor template (a 6 kb LacZ or 8.7 kb human CFTR expression cassette) into cultured pig cells. We demonstrated precise integration of each donor into the GGTA1 safe harbor through Cas9-induced homology directed repair with 3 kb homology arms. In addition, we showed that both LacZ and hCFTR were persistently expressed in transduced cells. Furthermore, we created a CFTR-deficient cell line for testing CFTR correction. We detected hCFTR mRNA and protein expression in cells transduced with the hCFTR vector. We also demonstrated CFTR function in the CF cells transduced with the HD-Ad delivering the CRISPR-Cas9 system and hCFTR donor at late cellular passages using the membrane potential sensitive dye-based assay (FLIPR®). Combined with our previous report on gene delivery to pig airway basal cells, these data provide the feasibility of testing CRISPR/Cas9-mediated permanent human CFTR correction through HD-Ad vector delivery in pigs.
Get full access to this article
View all access options for this article.
References
1.
SosnayPR, SiklosiKR, Van GoorF, et al.Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet, 2013; 45:1160.
2.
CsanádyL, VerganiP, GadsbyDC. Structure, gating, and regulation of the CFTR anion channel. Physiol Rev, 2018; 99:707–738.
3.
BhagirathAY, LiY, SomayajulaD, et al.Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med, 2016; 16:174.
4.
SlyPD, GangellCL, ChenL, et al.Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med, 2013; 368:1963–1970.
PrayleA, WatsonA, FortnumH, et al.Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax, 2010; 65:654–658.
7.
HahnA, BurrellA, FanousH, et al.Antibiotic multidrug resistance in the cystic fibrosis airway microbiome is associated with decreased diversity. Heliyon, 2018; 4:e00795.
8.
RamseyBW, DaviesJ, McElvaneyNG, et al.A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med, 2011; 365:1663–1672.
9.
HarrisonMJ, MurphyDM, PlantBJ. Ivacaftor in a G551D homozygote with cystic fibrosis. N Engl J Med, 2013; 369:1280–1282.
10.
WainwrightCE, ElbornJS, RamseyBW, et al.Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med, 2015; 373:220–231.
KnowlesMR, HohnekerKW, ZhouZ, et al.A controlled study of adenoviral-vector–mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med, 1995; 333:823–831.
13.
AitkenML, MossRB, WaltzDA, et al.A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther, 2001; 12:1907–1916.
14.
WagnerJA, NepomucenoIB, MessnerAH, et al.A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther, 2002; 13:1349–1359.
15.
MossRB, MillaC, ColomboJ, et al.Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther, 2007; 18:726–732.
16.
GriesenbachU, PytelKM, AltonEWFW. Cystic fibrosis gene therapy in the UK and elsewhere. Hum Gene Ther, 2015; 26:266–275.
17.
KardaR, BuckleySMK, WaddingtonSN. Gene therapy with adeno-associated virus for cystic fibrosis. Am J Respir Crit Care Med, 2016; 193:234–236.
18.
GugginoWB, CebotaruL. Adeno-associated virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments. Expert Opin Biol Ther, 2017; 17:1265–1273.
19.
WangJ, DeClercqJJ, HaywardSB, et al.Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Res, 2015; 44:e30.
20.
BedellVM, WangY, CampbellJM, et al.In vivo genome editing using a high-efficiency TALEN system. Nature, 2012; 491:114.
21.
AirdEJ, LovendahlKN, MartinAS, et al.Increasing Cas9-mediated homology-directed repair efficiency through covalent tethering of DNA repair template. Commun Biol, 2018; 1:54.
22.
BreunigCT, DurovicT, NeunerAM, et al.One step generation of customizable gRNA vectors for multiplex CRISPR approaches through string assembly gRNA cloning (STAgR). PLoS One, 2018; 13:e0196015.
23.
RogersCS, StoltzDA, MeyerholzDK, et al.Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science, 2008; 321:1837–1841.
24.
StoltzDA, MeyerholzDK, PezzuloAA, et al.Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med, 2010; 2:29ra31–29ra31.
25.
GaliliU, ShohetSB, KobrinE, et al.Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem, 1988; 263:17755–17762.
26.
TsengY-L, KuwakiK, DorFJMF, et al.α1, 3-Galactosyltransferase gene-knockout pig heart transplantation in baboons with survival approaching 6 months. Transplantation, 2005; 80:1493–1500.
27.
ChoiK, ShimJ, KoN, et al.Production of heterozygous alpha 1, 3-galactosyltransferase (GGTA1) knock-out transgenic miniature pigs expressing human CD39. Transgenic Res, 2017; 26:209–224.
NottleMB, SalvarisEJ, FisicaroN, et al.Targeted insertion of an anti-CD2 monoclonal antibody transgene into the GGTA1 locus in pigs using Fok I-dCas9. Sci Rep, 2017; 7:8383.
30.
MuruveDA, CotterMJ, ZaissAK, et al.Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol, 2004; 78:5966–5972.
31.
KoehlerDR, SajjanU, ChowY-H, et al.Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia. Proc Natl Acad Sci U S A, 2003; 100:15364–15369.
32.
CaoH, OuyangH, GrasemannH, et al.Transducing airway basal cells with a helper-dependent adenoviral vector for lung gene therapy. Hum Gene Ther, 2018; 29:643–652.
33.
BerschneiderHM. Development of normal cultured small intestinal epithelial cell lines which transport Na and Cl. Gastroenterology, 1989; 96(Suppl. Pt 2):A41.
34.
ChowY-H, O'BrodovichH, PlumbJ, et al.Development of an epithelium-specific expression cassette with human DNA regulatory elements for transgene expression in lung airways. Proc Natl Acad Sci U S A, 1997; 94:14695–14700.
YeL, ChanS, ChowY-H, et al.Regulated expression of the human CFTR gene in epithelial cells. Mol Ther, 2001; 3:723–733.
37.
MaruyamaT, DouganSK, TruttmannMC, et al.Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol, 2015; 33:538.
38.
LiG, ZhangX, ZhongC, et al.Small molecules enhance CRISPR/Cas9-mediated homology-directed genome editing in primary cells. Sci Rep, 2017; 7:8943.
39.
SchwankG, KooB-K, SasselliV, et al.Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell, 2013; 13:653–658.
40.
PaixA, FolkmannA, GoldmanDH, et al.Precision genome editing using synthesis-dependent repair of Cas9-induced DNA breaks. Proc Natl Acad Sci U S A, 2017; 114:E10745–E10754.
41.
BakerO, TsurkanS, FuJ, et al.The contribution of homology arms to nuclease-assisted genome engineering. Nucleic Acids Res, 2017; 45:8105–8115.
42.
ZhangJ-P, LiX-L, LiG-H, et al.Efficient precise knockin with a double cut HDR donor after CRISPR/Cas9-mediated double-stranded DNA cleavage. Genome Biol, 2017; 18:35.
43.
KosickiM, TombergK, BradleyA. Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol, 2018; 36:765.
RobertF, BarbeauM, ÉthierS, et al.Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing. Genome Med, 2015; 7:93.
46.
OstedgaardLS, MeyerholzDK, ChenJ-H, et al.The ΔF508 mutation causes CFTR misprocessing and cystic fibrosis—like disease in pigs. Sci Transl Med, 2011; 3:74ra24–74ra24.
47.
WelshMJ, RogersCS, StoltzDA, et al.Development of a porcine model of cystic fibrosis. Trans Am Clin Climatol Assoc, 2009; 120:149.
48.
DannhofferL, Blouquit-LayeS, RegnierA, et al.Functional properties of mixed cystic fibrosis and normal bronchial epithelial cell cultures. Am J Respir Cell Mol Biol, 2009; 40:717–723.
49.
JohnsonLG, OlsenJC, SarkadiB, et al.Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet, 1992; 2:21–25.
50.
CooneyAL, AlaiwaMHA, ShahVS, et al.Lentiviral-mediated phenotypic correction of cystic fibrosis pigs. JCI Insight, 2016; 1:e88730.
51.
SteinesB, DickeyDD, BergenJ, et al.CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes. JCI Insight, 2016; 1:e88728.
52.
MolinskiSV, AhmadiS, HungM, et al.Facilitating structure-function studies of CFTR modulator sites with efficiencies in mutagenesis and functional screening. J Biomol Screen, 2015; 20:1204–1217.
53.
AhmadiS, BozokyZ, PaolaM, et al.Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia. NPJ Genomic Med, 2017; 2:12.
54.
CucchiariniM. Human gene therapy: novel approaches to improve the current gene delivery systems. Discov Med, 2016; 21:495–506.
55.
CrystalRG, McElvaneyNG, RosenfeldMA, et al.Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet, 1994; 8:42.
56.
LiW, ZhangL, JohnsonJS, et al.Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol Ther, 2009; 17:2067–2077.
57.
CooneyAL, SinghBK, LozaLM, et al.Widespread airway distribution and short-term phenotypic correction of cystic fibrosis pigs following aerosol delivery of piggyBac/adenovirus. Nucleic Acids Res, 2018; 46:9591–9600.
58.
MontoroDT, HaberAL, BitonM, et al.A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. Nature, 2018; 560:319.
59.
WatsonJK, RulandsS, WilkinsonAC, et al.Clonal dynamics reveal two distinct populations of basal cells in slow-turnover airway epithelium. Cell Rep, 2015; 12:90–101.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
